Impairments in degradation pathways implicate failed TDP-43 clearance as a primary disease mechanism in neurodegeneration and a variety of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS)16–19. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.